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Abstract
Background: Early treatment with tranexamic acid may reduce deaths after traumatic brain injury (TBI). In mild and
moderate TBI, there is a time to treatment interaction, with early treatment being most beneficial. Time to
treatment was recorded by clinicians and is subject to error. Using monitoring data from the CRASH-3 trial, we
examine the impact of errors in time to treatment on estimated treatment effects.
Methods: The CRASH-3 trial was a randomised trial of the effect of tranexamic acid on death and vascular
occlusive events in 12,737 TBI patients. This analysis includes the 8107 patients with a Glasgow coma scale score of
9 to 15 since previous analyses showed that these patients benefit most from early treatment. Clinician-recorded
time to treatment was checked against ambulance and hospital records for 1368/12,737 (11%) patients. Patients
who died were preferentially selected for monitoring and we monitored 36% of head injury deaths. We describe
measurement errors using Bland-Altman graphs. We model the effect of tranexamic acid on head injury death
using logistic regression with a time-treatment interaction term. We use regression calibration, multiple imputation
and Bayesian analysis to estimate the impact of time to treatment errors.
Results: Clinicians rounded times to the nearest half or full hour in 66% of cases. Monitored times were also
rounded and were identical to clinician times in 63% of patients. Times were underestimated by an average of
9 min (95% CI − 85, 66). There was more variability between clinician-recorded and monitored times in low- and
middle-income countries than in high-income countries. The treatment effect estimate at 1 h was greater for
monitored times OR = 0.61 (95% CI 0.47, 0.81) than for clinician-recorded times OR = 0.63 (95% CI 0.48, 0.83). All
three adjustment methods gave similar time to treatment interactions. For Bayesian methods, the treatment effect
at 1 h was OR = 0.58 (95% CI 0.43, 0.78). Using monitored times increased the time-treatment interaction term from
1.15 (95% CI 1.03, 1.27) to 1.16 (95% CI 1.05, 1.28).
Conclusions: Accurate estimation of time from injury to treatment is challenging, particularly in low resource
settings. Adjustment for known errors in time to treatment had minimal impact on the trial results.
Trial registration: ClinicalTrials.gov NCT01402882. Registered on 25 July 2011
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Introduction
In emergency situations, treatment effects may depend
on the time delay between the acute event and adminis-
tration of the trial intervention. The CRASH-3 trial [1]
showed that in patients with mild and moderate head in-
juries, tranexamic acid treatment reduced head injury
deaths. As in previous trials of tranexamic acid in life-
threatening bleeding, there was a strong time to
treatment (TTT) interaction. The CRASH-2 trial [2]
examined the effects of tranexamic acid in bleeding
trauma patients. The WOMAN trial [3] examined its ef-
fects in post-partum haemorrhage. Both trials showed
that tranexamic acid reduces death from bleeding when
given within 3 h of bleeding onset with no benefit when
given after 3 h. An individual patient data meta-analysis
[4] found that for every 15-min treatment delay, there
was a 10% reduction in effectiveness.
The CRASH-3 trial was conducted in 175 hospitals in
29 countries. Many patients were recruited in countries
without formal pre-hospital emergency medical services
(e.g. ambulance systems) and patients were often taken
to hospital by bystanders or family members in taxis or
private vehicles. In these cases, the time of injury was
not formally recorded and was estimated by a clinician
based on the location of injury and approximate trans-
port times. However, in low- and middle-income coun-
tries, patients are often taken to the nearest primary
healthcare centre, where they receive basic first aid be-
fore transfer to a tertiary hospital. In these situations, es-
timating the time of injury using location of injury and
transportation times can be highly inaccurate.
Random measurement error can bias estimates of re-
gression coefficients, reducing the apparent association
between an exposure and outcome [5, 6]. Error in
clinician-recorded TTT could obscure or weaken the
TTT interaction and this could have clinical implica-
tions. In clinical trials, risk-adapted approaches to moni-
toring include verifying a proportion of participants’
measurements to assess the extent and nature of any
errors and to adjust the analysis if necessary [7]. We
examined the impact of mismeasurement in clinician-
recorded TTT on treatment effects. We used three
established statistical methods to correct for mismeas-
urement in clinician-recorded TTT using a sample of
monitored patients.
Methods
We examined data from the CRASH-3 trial, a rando-
mised trial of the effect of tranexamic acid on death, dis-
ability and vascular occlusive events in 12,737 TBI
patients. The inclusion criteria were: adults with TBI,
who had a Glasgow coma scale score (GCS) ≤ 12 or any
intracranial bleeding on CT scan and no significant
extra-cranial bleeding. The primary outcome was head
injury death within 28 days. Of the 12,737 patients ran-
domised, clinician-recorded TTT was monitored for
1368 (11%) patients by comparing clinician-recorded
times with those based on data from ambulance and
hospital records.
In this analysis, we examine the effect of inaccuracy in
TTT estimates in 8107 patients with mild and moderate
head injury. In this population, there was evidence of
benefit from tranexamic acid treatment and evidence of
a time treatment interaction. Patients with mild to mod-
erate TBI had a baseline GCS of 9 to 15, and of these,
456 (6%) were monitored. Patients who died were pref-
erentially chosen for monitoring. Hospitals that recruited
a larger number of patients were monitored by visit.
Other hospitals were monitored by telephone. All pa-
tient details (including TTT, GCS, age and SBP) were
checked.
We estimated odds ratios and 95% confidence intervals
for the effect of tranexamic acid on head injury deaths
according to TTT using a multivariable logistic regres-
sion model (1):
logit p Y ¼ 1ð Þð Þ ¼ β0 þ β1X þ β2T þ β3XT
þ β4GCS þ β5SBP þ β6A ð1Þ
(Y = 1 is head injury death within 28 days, X is treat-
ment (tranexamic acid = 1, placebo = 0), T is TTT in
hours, A is age in years at the time of the acute event,
GCS is Glasgow coma scale and SBP is systolic blood
pressure in mmHg). We assume that clinician-recorded
time is measured with error and that the monitored time
more accurately reflects TTT.
Three methods (regression calibration, multiple im-
putation and a full Bayesian analysis) were used to adjust
for mismeasurement in clinician-recorded time. Each re-
quired the following two steps,
1) A model for the association between clinician-
recorded and monitored time was estimated from
the sample of patients who were monitored and
2) This fitted model was used to impute a monitored
time for the patients who were not in the
monitoring sample.
Within this framework, monitored time was assumed
to have a linear relationship with clinician time.
TM ¼ α0 þ α1TC þ α2Aþ α3SBP þ α4GCS þ e ð2Þ
where e~N(0, σ2), TM is the monitored time and TC is
the clinician-recorded time.
First, for regression calibration, model coefficients (Eq.
2) were estimated using the monitored data and used to
predict times in the unmonitored population. Confi-
dence intervals were calculated by bootstrapping.
Mansukhani et al. Trials          (2020) 21:681 Page 2 of 8
Second, we treated unmonitored patients as having
missing data and used multiple imputation as described
by Bartlett [8, 9]. Third, we examined the impact of
measurement error in a full Bayesian model, in which
monitored TTT for patients who are not monitored was
treated as another parameter to be estimated. For all
three methods, the effect of tranexamic acid on death
within 28 days was estimated from the model in Eq. 1
based on the actual data for monitored patients and im-
puted values for unmonitored patients. Further details of
the methods are given in the statistical methods section
of the Additional file 1.
Results
Of the 8107 patients with mild and moderate head in-
jury, 537 (7%) died from head injury within 28 days. Of
the 456 monitored patients, 186 (41%) died from head
injury within 28 days. Table 1 shows the characteristics
of the included patients stratified by monitoring status.
In 63% (287/456) of monitored patients, clinician-
recorded times and monitored time were the same.
Clinician-recorded times were less than monitored times
for 28% (128/456) and more than monitored times for
9% (41/456) of monitored patients.
Figure 1 shows a histogram of clinician-recorded
times. The most common TTT is at 2 h with the next
most commonly occurring TTT’s being at 3 h, 2 h 30
min, 1 h and 4 h. There was strong digit preference with
times rounded to half an hour in 20% and to the hour in
46% of patients. There was also strong digit preference
in the monitored times with times rounded to half an
hour in 21% and to the hour in 29% of patients (Add-
itional file 1: Figure 1).
The mean difference between clinician-recorded and
monitored TTT was − 9 min, indicating that clinicians
were more likely to underestimate TTT on average. The
differences ranged from the clinician-recorded time be-
ing 66min larger to 85 min smaller than the monitored
time (Additional file 1: Figure 2). Figure 2 shows Bland-
Altman graphs of clinician-recorded versus monitored
TTT by country income level. In low- and middle-
income countries, the mean difference was − 10min.
The differences ranged from the clinician-recorded time
being 74 min larger to 93min smaller than the moni-
tored time. In high-income countries, the mean differ-
ence was − 9 min. The differences ranged from the
clinician-recorded time being 44min larger to 61 min
smaller than the monitored time. The standard deviation
of the time difference was 38 min for all countries com-
bined, 42 min in low- and middle-income countries and
27min in high-income countries. There was strong evi-
dence that this time difference variance was larger in
low- and-middle compared to high-income countries
(F318,136 = 2.52, p < 0.0001).
Using regression and assuming a linear relationship
between monitored and clinician time (Eq. 2) R2 = 0.82.
Table 2 and Fig. 4 show the ORs and 95% CIs for the
effect of tranexamic acid by TTT based on clinician-
recorded time, monitored time and after using the
three statistical adjustment methods. The interaction
term is larger when monitored times were used. The
Table 1 The characteristics of the included patients stratified by
monitoring status
Monitored Unmonitored
(n = 456) (n = 7651)
Received TXA 229 (50%) 3852 (50%)
Head injury death 186 (41%) 351 (5%)
Time to treatment
Mean (SD) 156 min (86 min) 178 min (108 min)
≤ 1 51 (11%) 955 (12%)
1–2 128 (28%) 2242 (29%)
2–3 185 (41%) 2117 (28%)
3–4 36 (8%) 705 (9%)
4–5 18 (4%) 572 (7%)
5–6 21 (5%) 500 (7%)
6–7 10 (2%) 375 (5%)
7–8 7 (2%) 185 (2%)
Sex
Male 368 (81%) 5937 (78%)
Female 88 (19%) 1713 (22%)
Unknown 0 (0%) 1 (0%)
GCS
Moderate 9–12 297 (65%) 3535 (46%)
Mild 13–15 159 (35%) 4051 (53%)
Unknown 0 (0%) 65 (1%)
SBP (mmHg)
0–89 7 (2%) 57 (1%)
90–119 94 (21%) 2546 (33%)
120–139 166 (36%) 2730 (36%)
140+ 189 (41%) 2300 (30%)
Unknown 0 (0%) 18 (0%)
Age (years)
Mean (SD) 51 (22) 43 (20)
0–15 0 (0%) 2 (0%)
16–24 62 (14%) 1628 (21%)
25–34 79 (17%) 1566 (20%)
35–44 42 (9%) 1172 (15%)
45–54 67 (15%) 1082 (14%)
55+ 206 (45%) 2201 (29%)
Baseline characteristics of mild and moderately injured patients in CRASH-3 by
monitoring status
N = 8107
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Fig. 1 Histogram showing digit preference in time to treatment for mild to moderately injured patients in CRASH-3. N = 8107. Time is from
monitoring where available else clinician-recorded
Fig. 2 Bland-Atman graphs by country income level. The graph on the left is for low- and middle-income countries (N = 319, bias = − 10 min,
upper limit of agreement = 74 min, lower limit of agreement = − 93 min). The graph on the right is for high-income countries (N = 137, bias = − 9
min, upper limit of agreement = 44 min, lower limit of agreement = − 61 min). The magnitude of the bias and the gap between the limits of
agreement are larger in low- to middle-income compared to high-income countries
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adjustment methods all give similar results in the
CRASH-3 data and increase the time treatment inter-
action further.
Figure 3 shows the effect of tranexamic acid on head
injury death by TTT (and provides a graphical represen-
tation of the first column of Table 2). The odds ratio for
the treatment effect increases with time. There is a 10%
reduction in treatment effectiveness for every 20-min in-
crease in TTT (Fig. 3).
Discussion
In the CRASH-3 trial, clinicians often underestimated
TTT with mismeasurement being greater in low- and
middle-income countries than in high-income countries.
Adjustment for known errors in TTT had little impact
on the results although effect estimates were slightly
larger. Our results suggest that early treatment with
tranexamic acid might be even more important than
previously reported.
Table 2 The ORs and 95% CIs for the effect of tranexamic acid by TTT based on clinician-recorded time, monitored time and after
using the three statistical adjustment methods
Clinician est. time CRASH-3 monitored time Regression calibration Multiple imputation Bayesian methods
Interaction 1.15 (1.03, 1.27) 1.16 (1.05, 1.28) 1.19 (1.05, 1.34) 1.18 (1.05, 1.33) 1.18 (1.06, 1.34)
0 h 0.55 (0.38, 0.78) 0.53 (0.37, 0.76) 0.49 (0.32, 0.73) 0.50 (0.33, 0.75) 0.49 (0.33, 0.73)
1 h 0.63 (0.48, 0.83) 0.61 (0.47, 0.81) 0.58 (0.42, 0.79) 0.59 (0.43, 0.80) 0.58 (0.43, 0.78)
2 h 0.72 (0.58, 0.89) 0.71 (0.58, 0.88) 0.69 (0.55, 0.86) 0.69 (0.56, 0.87) 0.69 (0.55, 0.86)
3 h 0.83 (0.69, 1.00) 0.83 (0.69, 0.99) 0.82 (0.68, 0.99) 0.82 (0.68, 0.99) 0.82 (0.68, 0.98)
4 h 0.95 (0.76, 1.18) 0.96 (0.77, 1.19) 0.97 (0.78, 1.22) 0.97 (0.78, 1.21) 0.97 (0.78, 1.21)
5 h 1.09 (0.82, 1.44) 1.11 (0.84, 1.47) 1.15 (0.85, 1.58) 1.15 (0.84, 1.56) 1.15 (0.85, 1.55)
6 h 1.25 (0.87, 1.80) 1.29 (0.89, 1.85) 1.37 (0.91, 2.10) 1.35 (0.90, 2.03) 1.36 (0.92, 2.03)
7 h 1.43 (0.91, 2.27) 1.49 (0.94, 2.35) 1.63 (0.97, 2.80) 1.60 (0.95, 2.68) 1.61 (0.98, 2.68)
8 h 1.64 (0.94, 2.86) 1.73 (0.99, 3.00) 1.94 (1.02, 3.75) 1.89 (1.00, 3.55) 1.90 (1.04, 3.55)
The effect of monitoring and statistical adjustment methods on the results of CRASH-3 for mild and moderately injured patient. N = 8107. There are 537 head
injury deaths in this population. Monitoring of TTT was carried out on 456 individuals. Interaction refers to the time treatment interaction term in the substantive
model (Eq. 1). The “0 h,” “1 h,” etc., row headings refer to the treatment effect OR at that time point
Fig. 3 Tranexamic acid effectiveness in preventing death due to TBI versus time to treatment. Mild and moderately injured patients only. N =
8107, number of head injury deaths = 537. Time to treatment is from monitoring where available else clinician-recorded
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We restricted our analysis to mild and moderately in-
jured patients since there was a strong time treatment
interaction in this subgroup. We excluded severely in-
jured patients because there was no evidence of a time
treatment interaction in these patients [1].
In over half of monitored patients, clinician-recorded
and monitored times were identical. However, this does
not mean that clinician-recorded times are accurate. For
many patients, monitors had no additional information
on which to base their assessments and so it is not sur-
prising that the clinician-recorded times did not change
after monitoring. There was strong digit preference in
both clinician-recorded and monitored times which sug-
gest inaccuracy in both sets of measurements. Time of
treatment is usually recorded in the patient notes but
the time of injury is often uncertain. In high-income
countries, ambulance records often provide information
on the approximate time of injury, but in low- and
middle-income settings, these records are often absent.
Accordingly, the variance of the difference between
clinician-recorded and monitored TTT was larger in
low- and middle-income compared to high-income
countries. In low- and middle-income settings, time of
injury was often estimated from bystander reports of the
location of injury and estimated travel times to the treat-
ing hospital. However, because patients are often taken
to the nearest healthcare centre before transfer to the
randomising hospital, this method can lead to substan-
tial underestimation of the time since injury.
It seems reasonable to assume that clinicians are more
likely to underestimate than overestimate TTT. This as-
sumption is consistent with the general psychological lit-
erature of time perception and with studies of time to
treatment estimation in trauma patients [10–14]. In this
study, clinician-recorded TTT was less than monitored
TTT for 28% and more than monitored TTT for 9% of
monitored individuals. It is well known that random
mismeasurement of an exposure variable biases its ap-
parent effect on the outcome variable towards zero [5,
6]. In the CRASH-3 trial, there was a small increase in
treatment effect after adjustment for mismeasurement.
Because we could not fully adjust for mismeasurement,
it is likely that the treatment effect and particularly its
interaction with TTT may be underestimated.
Accurate estimation of time to treatment is also im-
portant in stroke [15] and myocardial infarction [16]
where treatment is only effective if given within a
limited time window. In both of these areas, novel al-
ternatives to patient reported times have been pro-
posed [17, 18].
The three statistical methods, each of which assume a
linear relationship between monitored and clinician
time, gave similar results. Bartlett [19] found that the full
Bayesian analysis gave more biased results than regres-
sion calibration for small effect sizes when the reliability
of the imputation model was low. However, regression
calibration can underestimate regression coefficients for
large effect estimates [20]. Neither scenario is true for
these data. Having 94% missingness is unusual when im-
puting missing data. However, in this case, we have a
large number (456) of monitored times for reliable im-
putation. The large sample size and the large number of
monitored values are important strengths of our study.
Of the three statistical adjustment methods, we found
regression calibration the easiest to implement requiring
only a small amount of non-standard code to estimate
confidence intervals by bootstrapping. For MI and the
full Bayesian analysis, a number of freely available soft-
ware packages are available (for example JAGS [21],
OpenBUGS [22], STAN [23], SMCFCS [24]). However,
Fig. 4 The effect of monitoring and statistical adjustment methods on the treatment effectiveness of tranexamic acid verses time to treatment.
N = 8107, number of head injury deaths = 537. CRASH-3 monitored time consists of monitored time where available else clinician-recorded
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these packages are not routinely used by applied statisti-
cians in trials units.
Conclusions
Randomised trials of potentially time critical treatments
need to consider measurement error in estimated TTT.
Validation studies may be necessary but identifying the
gold standard measurement is challenging in acute
settings.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04623-5.
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